Enrollment of oral powder T-1101 OPC phase trial has completed in Taiwan
T-1101, oral powder for constitution (OPC), from Taivex has completed the phase I trial in Oct, 2019. Total 21 patients have received T-1101 (Tosylate) OPC treatment in 4 clinical trial centers. According to the Phase clinical data, T-1101 has initially proved its safety and efficacy. Taivex will continue the development of T-1101 to further clinical …
Enrollment of oral powder T-1101 OPC phase trial has completed in Taiwan Read More »